Drug Profile


Alternative Names: A12; IMC-A12; LY3012217; NSC 742460

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Developer ImClone Systems; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Thymoma

Most Recent Events

  • 01 Jul 2016 ImClone completes its phase II trial for Neuroendocrine tumours in (NCT00781911)
  • 30 Jun 2016 Eli Lilly completes its phase II trial for Non-small cell lung cancer in US, Argentina, Brazil, Canada, EU, Israel and Turkey (NCT01232452)
  • 01 May 2016 National Cancer Institute completes a phase I trial in Hepatocellular carcinoma (Combination therapy, Late stage disease, First-line therapy, Unresectable) in USA (NCT01008566)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top